Results 211 to 220 of about 2,685,828 (313)
Uncertainty Quantification of Fatigue Life for Cement-Stabilized Cold Recycled Mixtures Using Probabilistic Programming. [PDF]
Liu H +5 more
europepmc +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Bilateral posterior tibial nerve stimulation as a neuromodulation strategy for obstructed defecation: a randomized controlled trial. [PDF]
Abouelnasr AA, Hany M.
europepmc +1 more source
The Value of a Statistical Life and the Coefficient of Relative Risk Aversion
Louis Kaplow
openalex +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
The relationship between perceived social support and quality of life among hospitalized patients with schizophrenia. [PDF]
Wakim ML +4 more
europepmc +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Enhanced family caregiving improves quality of life, resilience, and hope review in POST-SPINAL SURGERY patients: A Quasi-Experimental study. [PDF]
Zamani MR +5 more
europepmc +1 more source
Age Variations in Workers' Value of Statistical Life
Joseph E. Aldy, W. Kip Viscusi
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

